Drug discontinuation: Palbociclib Capsule (IBRANCE)
FDA lists 2 presentations as To Be Discontinued. Companies: Pfizer Inc..
- Published by source
- 2026-04-22
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Pfizer Inc.
- Products
- Palbociclib Capsule IBRANCE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
- Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-04-22
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1047 | new | 2026-10-22 | cec062f9b343…a5cfd0 | 1d8d6ba2a7e6…fc2ce6 |
Chain head: #1076 8ad5adc30b9b…88ce20